Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC

For patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy, treatment selection remains challenging because of aggressive disease biology, high symptom burden, limited survival expectations, and variable access to emerging therapies across Europe. This podcast examines European expert perspectives on the evolving role of TROP-2–directed antibody–drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, with attention to treatment sequencing, reimbursement barriers to recent approvals, toxicity-informed treatment selection, ocular and pulmonary toxicity monitoring, and care team readiness for implementing ADC-based therapy in routine practice.